[Clinical and electrophysiologic changes produced by (--) eburnamonine in acute and post-acute stages of head injuries].
Two groups of patients suffering from cranial trauma have been submitted to a double-blind acute (1-2 per phlebo ampules/die for 7-10 days) and chronic (1 i.m. ampule for 30 days) at random treatment, respectively with (--) Eburnamonine and Papaverine. The evaluation of the clinical symptoms (state of consciousness, neurologic and post-traumatic symptoms) and of some electrophysiological responses (REG, visual and somato-sensorial evoked potentials) were investigated in basal conditions, during the acute stage, at the end of the chronic treatment and 30 days after the drugs withdrawal. The results showed (--) Eburnamonine to induce a superior improvement than Papaverine of some clinical symptoms (motor disorders, retrograde amnesia, vertigo) and of cortical bioelectrical activity, as rheoencephalographic data and reduction in early latencies of evoked response to somato-sensorial stimulation (SEP) revealed. Local and systemic tolerability was good with both drugs; a slight hypotensive action, more marked with Papaverine, was noted at the end of the treatment.
D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D000368:Aged; D000648:Amnesia, Retrograde / Q000188:drug therapy; D001930:Brain Injuries / Q000188:drug therapy*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009069:Movement Disorders / Q000188:drug therapy; D009122:Muscle Hypertonia / Q000188:drug therapy; D010208:Papaverine / Q000627:therapeutic use*; D014474:Unconsciousness / Q000188:drug therapy; D014665:Vasodilator Agents / Q000627:therapeutic use*; D014717:Vertigo / Q000188:drug therapy; D014748:Vinca Alkaloids / Q000627:therapeutic use*
D014665:Vasodilator Agents; D014748:Vinca Alkaloids; D010208:Papaverine; C016422:eburnamonine
Modificazioni cliniche ed elettrofisiologiche indotte dalla (--) eburnamonina nei traumatizzati cranici in fase acuta e post-acuta.